Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas

Clinical Cancer Research

Volumn 14, Issue 16, 2008, Pages 5166-5172

  Heimberger, Amy B ^a,c   Abou Ghazal, Mohamed ^a   Reina Ortiz, Chantal ^a   Yang, David S ^a   Sun, Wei ^a   Qiao, Wei ^b   Hiraoka, Nobuyoshi ^d   Fuller, Gregory N ^c  

^a Department of Neurosurgery ^*  (Japan)

^b Division of Quantitative Sciences Department of Pathology   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TISSUE; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHILD; CONTROLLED STUDY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; BRAIN TUMOR; CELL LINEAGE; FEMALE; FLOW CYTOMETRY; GLIOMA; IMMUNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; T LYMPHOCYTE SUBPOPULATION; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 52649169692     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0320     Document Type: Article

References (43)

1. Brooks WH, Markesbery WR, Gupta GD, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978;4:219-24.
2. von Hanwehr Rl, Hofman FM, Taylor CR, Apuzzo ML. Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 1984;60:1138-47.
3. Strik HM, Stoll M, Meyermann R. Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res 2004;24:37-42.
4. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) Tcells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
5. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatoryTcells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002:169: 2756-61.
6. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory Tcells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
7. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65: 2457-64.
8. Miller AM, Lundberg K, Ozenci V, et al. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177:7398-405.
9. Fecci PE, Mitchell DA,Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006:66: 3294-302.
10. Hussain SF,Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006;8:261 -79.
11. Andaloussi AE, Lesniak MS. An increase in CD4+CD25+F0XP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-oncol 2006;8:234-43.
12. Jordan JT, Sun WH, Hussain SF, DeAngulo G, Prabhu SS, Heimberger AB. Preferential migration of regulatory T cells mediated by glioma-secreted che-mokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008;57:123- 31.
13. Kobayashi N, Hiraoka N,YamagamiW, etal. FOXP3+regulatoryTcells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13:902-11.
14. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic Tcells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-93.
15. Hiraoka N, Onozato K, KosugeT, Hirohashi S. Prevalence of FOXP3+ regulatoryTcells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34.
16. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-4+CD25+ Tcells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007; 13:2075-81.
17. Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006:12: 4294-305.
18. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatoryTcells and restoresTand NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641 -8.
19. Heimberger AB, McGary E, Suki D, et al. Loss of the AP-2α transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005;11: 267-72.
20. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames: Iowa State University Press; 1980.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
23. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFR-vlll in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462-6.
24. Barnett JA, Urbauer DL, Murray Gl, Fuller GN, Heimberger AB. CYP1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res 2007; 13:3559-67.
25. El Andaloussi A, Lesniak MS. CD4+ CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007;83:145-52.
26. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25.
27. Archer G, Bigner D, Friedman A, et al. Dendritic cell vaccine for intracranial tumors I (DC Victori Trial). Society for Neuro-Oncology, Education Day and Ninth Annual Scientific Meeting, Toronto, Ontario, Canada, 2004.
28. Heimberger AB, Hussain SF, Suki D, et al. An epidermal growth factor receptor variant III peptide vaccination appears promising in newly diagnosed GBM patients: Preliminary results of a randomized phase II clinical trial. 74th Annual Meeting of the American Association of Neurological Surgeons, San Francisco, CA 2006.
29. Plautz GE, Miller DW, Barnett GH, et al.Tcell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6:2209-18.
30. Wheeler CJ, Das A, Liu G,Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10: 5316-26.
31. Yu J, Liu G,Ying H, Yong W, Black K, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64: 4973-9.
32. Yu J,Wheeler C, Zeltzer P, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-7.
33. Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ Tcell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007;13:2158-67.
34. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory Tcells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
35. Dey M, Hussain SF, Heimberger AB. The role of glioma microenvironment in immune modulation: Potential targets for intervention. Lett Drug Des Discov 2006;3:443-51.
36. Safdari H, Hochberg FH, Richardson EP, Jr. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 1985;23:221 -6.
37. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/reg-ulatoryTcell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005:102:18538-43.
38. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxicTcells but not regulatoryT cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006;12:3355-60.
39. Badoual C, Hans S, Rodriguez J, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12: 465-72.
40. AlvaroT, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory Tcells. Clin Cancer Res 2005;11:1467-73.
41. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In situ analysis of FOXP3+ regulatoryTcells in human colorectal cancer. J Transl Med 2006;4:52.
42. Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL. Tcell receptor-mediated signaling is defective in Tcells obtained from patients with primary intracranial tumors. J Immunol 1997;159: 4415-25.
43. Miescher S.WhitesideTL, deTribolet N, von Fliedner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 1988;68: 438-48.